Related Experiment Video
Updated: Mar 5, 2026
09:37
Navigating MARRVEL, a Web-Based Tool that Integrates Human Genomics and Model Organism Genetics Information
Published on: August 15, 2019
10.6K
BRIDG: a domain information model for translational and clinical protocol-driven research
Lauren B Becnel1,2, Smita Hastak3, Wendy Ver Hoef3
1Clinical Data Interchange Standards Consortium, Austin, TX, USA.
Summary
The Biomedical Research Integrated Domain Group (BRIDG) model enables data interoperability across disparate health systems. This open-source model integrates clinical and translational research concepts for seamless data exchange.
Area of Science:
- Biomedical Informatics
- Health Data Standards
Background:
- Integrating biological, translational, and clinical data with health systems is challenging due to disparate data storage.
- Lack of data exchange capabilities in electronic systems hinders comprehensive analysis.
Purpose of the Study:
- To introduce the Biomedical Research Integrated Domain Group (BRIDG) model for standardized biomedical data exchange.
- To facilitate interoperability by providing a common understanding of research and healthcare semantics.
Main Methods:
- BRIDG is an open-source Unified Modeling Language (UML) class model.
- Developed using use cases and harmonized with existing data models.
Main Results:
- The BRIDG model version 4+ incorporates clinical and translational research concepts.
- Includes subdomains for Protocol Representation, Study Conduct, Adverse Events, Regulatory, Statistical Analysis, Experiment, Biospecimen, and Molecular Biology.
Conclusions:
- BRIDG is an established standard (CDISC, HL7, ISO) used in software development.
- Future evolution will focus on clinical imaging, pathology, ontology, and vocabulary support.
- BRIDG 4.1.1 and prior releases are publicly available.
Related Concept Videos
01:29Translational Regulation
732
Translational regulation in prokaryotes ensures efficient protein synthesis by controlling ribosome access to mRNA. This regulation is mediated by secondary RNA structures, including translational riboswitches, RNA thermometers, and small RNAs (sRNAs), which respond to intracellular and environmental signals to modulate gene expression.Translational RiboswitchesRiboswitches in the leader region of mRNAs can regulate translation by altering the accessibility of the Shine-Dalgarno (SD) sequence,...
732
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
510
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
510
02:28Leaky Scanning
5.8K
During most eukaryotic translation processes, the small 40S ribosome subunit scans an mRNA from its 5' end until it encounters the first start AUG codon. The large 60S ribosomal subunit then joins the smaller one to initiate protein synthesis. The location of the translation initiation is largely determined by the nucleotides near the start codon as there may be multiple translation initiation sites present on the mRNA. Marilyn Kozak discovered that the sequence RCCAUGG (where R...
5.8K
01:11Clinical Trials: Overview
5.2K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.2K
02:07Improving Translational Accuracy
15.3K
Base complementarity between the three base pairs of mRNA codon and the tRNA anticodon is not a failsafe mechanism. Inaccuracies can range from a single mismatch to no correct base pairing at all. The free energy difference between the correct and nearly correct base pairs can be as small as 3 kcal/ mol. With complementarity being the only proofreading step, the estimated error frequency would be one wrong amino acid in every 100 amino acids incorporated. However, error frequencies observed in...
15.3K
02:07Improving Translational Accuracy
3.7K
3.7K